Close Menu

NEW YORK (GenomeWeb) – AMRI has announced a strategic alliance with Bruker Daltonics and HighRes Biosolutions to implement new mass spectrometry technology in drug discovery.

AMRI, a contract research organization, will implement Bruker Daltonics' MALDI PharmaPulse system at its Integrated Drug Discovery Center. Under the terms of the alliance, Bruker Daltonics and HighRes will train and consult with AMRI researchers as they develop protocols for high-throughput screening in drug discovery.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.